title: Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.
abstract: BACKGROUND
  Selective serotonin reuptake inhibitors (SSRIs) are often described as having a delayed onset of effect in the treatment of depression. However, some trials have reported clinical improvement as early as the first week of treatment.
  
  
  OBJECTIVE
  To test the alternative hypotheses of delayed vs early onset of antidepressant action with SSRIs in patients with unipolar depression.
  
  
  METHODS
  Trials identified by searching CENTRAL, The Cochrane Collaboration database of controlled trials (2005), and the reference lists of identified trials and other systematic reviews.
  
  
  METHODS
  Randomized controlled trials of SSRIs vs placebo for the treatment of unipolar depression in adults that reported outcomes for at least 2 time points in the first 4 weeks of treatment (50 trials from >500 citations identified). Trials were excluded if limited to participants older than 65 years or specific comorbidities.
  
  
  METHODS
  Data were extracted on trial design, participant characteristics, and outcomes by a single reviewer.
  
  
  RESULTS
  Pooled estimates of treatment effect on depressive symptom rating scales were calculated for weeks 1 through 6 of treatment. In the primary analysis, the pattern of response seen was tested against alternative models of onset of response. The primary analysis incorporated data from 28 randomized controlled trials (n=5872). A model of early treatment response best fit the experimental data. Treatment with SSRIs rather than placebo was associated with clinical improvement by the end of the first week of use. A secondary analysis indicated an increased chance of achieving a 50% reduction in Hamilton Depression Rating Scale scores by 1 week (relative risk, 1.64; 95% confidence interval, 1.2-2.25) with SSRI treatment compared with placebo.
  
  
  CONCLUSIONS
  Treatment with SSRIs is associated with symptomatic improvement in depression by the end of the first week of use, and the improvement continues at a decreasing rate for at least 6 weeks.
authors.affiliation: Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, England. matthew.taylor@psych.ox.ac.uk
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Taylor
authors.forename: Nick
authors.initials: N
authors.lastname: Freemantle
authors.forename: John R
authors.initials: JR
authors.lastname: Geddes
authors.forename: Zubin
authors.initials: Z
authors.lastname: Bhagwagar
mesh_terms: D000328:Adult; D000367:Age Factors; D016001:Confidence Intervals; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012306:Risk; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors